The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
To read the full story
Related Article
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- JCR to Focus on Partnerships as Core of Growth Strategy: Vice President
March 30, 2022
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- JCR Hooks Up with Takeda on Global Expansion of Hunter Syndrome Drug
October 1, 2021
BUSINESS
- TGCV Drug CNT-01 Misses Goal in Japan PIIb/III Study: Toa Eiyo
June 26, 2024
- Tagrisso Plus Chemo Now Allowed to Treat EGFR Lung Cancer: AstraZeneca
June 26, 2024
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- Rexulti’s PTSD Filing Clinches FDA Acceptance for Review: Otsuka/Lundbeck
June 26, 2024
- Santen CEO Snares 191 Million Yen in Annual Pay, Workforce Down by 131
June 26, 2024
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…